Pathogenic variants in the ATP8B1 gene cause a rare liver disorder within the spectrum of familial intrahepatic cholestasis. Alteration of the FIC1 protein compromises the stability of canalicular membranes and promotes the accumulation of bile acids, producing pruritus, jaundice, and progressive liver disease.
Familial intrahepatic cholestasis (ATP8B1 gene)
Cholestasis intrahepatic familial related to the ATP8B1 gene is usually classified as ATP8B1 deficiency or progressive familial intrahepatic cholestasis type 1 (PFIC1). This gene encodes FIC1, a P-type ATPase involved in maintaining the proper distribution of phospholipids in the canalicular membrane of hepatocytes. When FIC1 does not function properly, the membrane becomes more vulnerable to the detergent effect of bile acids, and bile flow is altered. This leads to cholestasis, accumulation of bile components, and progressive liver damage.
It is transmitted in an autosomal recessive pattern: two pathogenic copies of ATP8B1 are required to develop the disease, one from each parent. Biallelic variants can produce a clinical spectrum ranging from severe infantile-onset PFIC1 to benign recurrent intrahepatic cholestasis type 1 (BRIC1), with an episodic and milder course. The combined incidence of progressive familial intrahepatic cholestases is estimated at around 1 in 50,000–100,000 births.
Symptoms
Symptoms usually begin in the first months of life with intense itching, recurrent or persistent jaundice, pale stools, dark urine, and growth delay. Hepatomegaly or hepato-splenomegaly and fat-soluble vitamin deficiencies (A, D, E, and K) may appear. ATP8B1 deficiency can be accompanied by extrahepatic manifestations, such as chronic diarrhea, pancreatitis, failure to thrive, and sensorineural deafness. Progression varies: some patients develop fibrosis, cirrhosis, and liver failure, while others present with recurrent episodes of cholestasis.
Disease management
Management aims to reduce cholestasis, relieve pruritus, and prevent nutritional and hepatic complications. It includes hepatological monitoring, adequate caloric intake, fat-soluble vitamins, and, in some patients, ursodeoxycholic acid. For pruritus, medications such as rifampicin or exchange resins may be used, and ileal bile acid transporter (IBAT) inhibitors, such as odevixibat or maralixibat, can be considered depending on indication and availability. If medical control fails, biliary diversion or liver transplantation may be considered, although extrahepatic manifestations may persist.
Genes analyzed
Bibliography
A Siddiqi I, Tadi P. Progressive Familial Intrahepatic Cholestasis. 2023 Jul 3. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
Bull LN, Morotti R, Squires JE. ATP8B1 Deficiency. 2001 Oct 15 [updated 2021 Sep 9]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.
Vitale G, Mattiaccio A, Conti A, et al. Genetics in Familial Intrahepatic Cholestasis: Clinical Patterns and Development of Liver and Biliary Cancers: A Review of the Literature. Cancers (Basel). 2022 Jul 14;14(14):3421.
